Genetic testing for skin medicines is still mostly experimental, according to Gram Research analysis of a 2026 review in Pharmacogenomics. Methotrexate had the strongest evidence, with gene differences linked to treatment response and side effects, while secukinumab and isotretinoin showed no clear genetic effect.
According to research reviewed by Gram, genetic testing may someday help doctors choose the right medicine for people with skin conditions such as psoriasis, eczema, acne, and rosacea. Our genes shape how the body processes a drug, which can affect how well it works and how likely side effects are. This review looked at medical studies published from January 2010 through April 2026. The strongest evidence involved methotrexate, a widely used medicine, where certain gene differences were linked to how patients respond and to side effects. For two other treatments, secukinumab and isotretinoin, the review found no clear genetic effect. Overall, the authors concluded that most of this work is still experimental, and larger, well-designed studies are needed before gene-guided treatment becomes routine in dermatology clinics.
Key Statistics
A 2026 review in the journal Pharmacogenomics, covering PubMed studies from January 2010 to April 2026, found that methotrexate had the strongest pharmacogenetic evidence among the skin therapies examined.
A 2026 review of skin disease research identified pharmacogenetic guidelines for only three drugs: cyclosporine A, methotrexate, and carvedilol.
A 2026 review in Pharmacogenomics found no clinically relevant genetic effect for secukinumab, used in psoriasis, or isotretinoin, used in acne.
The Quick Take
- What they studied: Whether a person’s genes can help doctors predict which prescription skin medicines will work well and which may cause harmful side effects.
- Who participated: This was a review of previously published research, not a study with its own group of patients. The authors searched the PubMed medical database for studies from January 2010 to April 2026. The total number of people across the reviewed studies was not reported.
- Key finding: Methotrexate had the strongest evidence, with certain gene differences linked to how well patients responded to it and to side effects. Secukinumab and isotretinoin showed no clear genetic effect. Most other skin treatments have early, mixed, or missing evidence.
- What it means for you: Gene-based prescribing is not standard care for skin conditions yet. If you take one of these medicines, do not change your treatment based on this review. Bring any questions about side effects or dosing to your dermatologist.
The Research Details
This paper is a structured literature review with narrative synthesis. In plain terms, the authors searched PubMed and MEDLINE, two large databases of medical research, for studies from January 2010 to April 2026. They focused on treatments taken by mouth or by injection for four common skin conditions: psoriasis, atopic dermatitis (eczema), acne vulgaris, and rosacea.
The team read and compared the findings from genetic studies, combined analyses, and published treatment guidelines. Rather than pooling all the data into a single statistical result, they summarized the evidence for each medicine and sorted it into categories: strong, emerging, inconsistent or exploratory, and no clear effect.
This approach gives a broad overview of a fast-moving field. It is useful for identifying which medicines have been studied the most, but it does not produce a single new number on how much genes change treatment outcomes.
Doctors often rely on trial and error to find the right skin medicine and dose. Genes can influence how the body breaks down and moves drugs, so knowing a person’s genetic profile could potentially reduce wasted time and side effects. A broad review helps show where that idea already has support and where it does not.
The paper was published in Pharmacogenomics, a peer-reviewed journal focused on how genes affect drug response. Peer review means outside experts checked the work before publication. However, this is a narrative review, not a systematic meta-analysis, so the authors’ conclusions depend partly on their judgment about which studies to include and how to weigh them. The number of participants in the underlying studies was not reported in the summary provided.
What the Results Show
The clearest finding concerns methotrexate, a medicine used for psoriasis and other inflammatory conditions. The review found that variations in genes involved in folate metabolism, which is how the body uses a B vitamin needed for cell growth, and in drug transport were associated with how well patients responded to methotrexate and with side effects. This is the most developed area in the paper.
The review also identified pharmacogenetic guidelines for three drugs: cyclosporine A, methotrexate, and carvedilol. Carvedilol is a heart medication, included because it is used in some patients with skin disease. Guidelines mean professional groups have reviewed the evidence and offered recommendations about when gene information could guide dosing or choice.
For several other treatments, the evidence is promising but not yet firm. The authors describe emerging evidence for cyclosporine A, glucocorticoids (steroid medicines), adalimumab, and some targeted therapies. These findings suggest that genes may influence how these medicines work, but the results are not consistent enough to guide everyday decisions.
For secukinumab, used in psoriasis, and isotretinoin, used in severe acne, current data do not show a clinically relevant genetic effect. This means that, based on this review, knowing a patient’s genes is not expected to change how these medicines are chosen or dosed.
Many treatments in the review have evidence that is exploratory, inconsistent, or missing entirely. The authors note that results often differ from one study to the next, which makes it hard to know which gene markers are reliable. Pharmacogenetics in dermatology is therefore still largely a research field rather than a routine clinical tool. The authors also emphasize that the outcomes measured in studies are not always standardized, which makes comparisons across studies harder.
Pharmacogenetics, the study of how genes affect drug response, is well established in some areas of medicine, such as certain cancer and heart drugs. This review suggests that dermatology has not reached the same stage. The findings fit the broader view that gene testing is most useful when a drug has a clear, repeatable link to specific genes and when guidelines are based on consistent results.
This review does not give a single overall number for how much genes change treatment results. Because it is a narrative review rather than a statistical pooling of data, the conclusions depend on the authors’ selection and interpretation of studies. The search was limited to PubMed and MEDLINE, so relevant research in other databases may have been missed. Many of the underlying studies appear to be small, and the paper notes that the outcomes measured often differ. The authors themselves state that robust validation and shared clinical endpoints are still needed.
The Bottom Line
Based on this review, gene testing should not yet be used to choose or dose skin medicines in routine practice. Confidence is highest for methotrexate, where gene links to response and side effects are the most developed, but even here the authors call for further validation. Confidence is low for most other treatments, and the review found no clear genetic effect for secukinumab or isotretinoin. People should not stop or change prescribed medicines based on this research alone.
People with psoriasis, eczema, acne, or rosacea who are considering or currently taking systemic medicines, such as methotrexate, may find this topic relevant. Clinicians and researchers working on personalized dermatology will also find the review useful. People who take none of these medicines, or who are already happy with their treatment, have little need to act on these findings right now.
Gene-guided skin treatment is still in the research phase, so benefits for everyday patients are not expected in the near term. The authors say robust validation and standardized endpoints must come first, and that process typically takes years of additional studies. Anyone starting or changing a medicine should expect their doctor to rely on standard dosing and monitoring for now.
Frequently Asked Questions
Can my genes determine which psoriasis or eczema medicine will work best for me?
Not yet for most people. A 2026 review in Pharmacogenomics found that gene-guided prescribing for skin conditions is still largely investigational. Methotrexate has the strongest supporting evidence, while most other treatments have limited or inconsistent data.
Does genetic testing predict side effects of methotrexate for skin disease?
Gene variants involved in folate metabolism and drug transport have been linked to methotrexate response and side effects in research reviewed in 2026. These links are the strongest among skin therapies, but the review says they need further validation before routine clinical testing.
Is isotretinoin for acne affected by my genetics?
Current data do not show a clinically relevant genetic effect on isotretinoin, according to a 2026 review in Pharmacogenomics. The same review found no clear genetic impact for secukinumab. Follow your dermatologist’s dosing and monitoring instructions regardless of genetic background.
Should I ask my dermatologist for a pharmacogenetic test before starting skin treatment?
Routine testing is not generally recommended for skin conditions yet, because the 2026 review concluded that robust validation is still needed. Some clinicians may consider testing for drugs with established guidelines, such as methotrexate, so ask your doctor about your options.
Want to Apply This Research?
- Log each dose of any prescribed skin medicine, along with the date, and rate your skin condition on a simple 0 to 10 scale once a week. Note any side effects such as nausea, fatigue, or mouth sores, with a severity rating. Over several months, this produces a clear personal record to share with your dermatologist.
- Set a weekly reminder to complete a short check-in in the app that covers skin severity, medication timing, and side effects. Use the app to write down questions for your next appointment, such as whether genetic testing is appropriate for your specific medicine.
- Review your logs monthly and look for patterns, such as flares that follow missed doses or side effects that appear after a dose change. Keep a running list of any genetic test results you have received, along with the medicines your doctor has prescribed. Share the summary with your care team at each visit and update it whenever your treatment changes.
This article summarizes a 2026 review of published research on genetics and skin disease medicines. It is for general education only and is not medical advice. Do not start, stop, or change any prescription based on this information. Talk with your dermatologist or other qualified health professional about your individual situation, including whether genetic testing is appropriate for you.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.